DYNABLAST PASTE 1CC 10-210-1060

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,distri report with the FDA on 2019-04-22 for DYNABLAST PASTE 1CC 10-210-1060 manufactured by Seaspine Inc..

Event Text Entries

[142613419] A device history record (dhr) review was conducted for lot 102268, and it was concluded that the products were inspected and accepted for use by the quality control department on 09/27/10 and met all specified parameters of the receiving inspection report (rir) with no associated nonconformances. Donor records were also reviewed, and product was approved on 09/23/09. The device was unable to be evaluated as the paste remained implanted. However, a medical review and assessment of the event was completed and determined that the reaction was a result of the restorative metals used in the procedure and that the fibrous strands were likely not related to the dynablast paste, as the material could not be identified in the pathology reports and dynablast paste is not comprised of fibrous strands. The reported allegation of post-operative reaction due to dynablast paste was not confirmed. A root cause of the fibrous strands was undetermined, and the reaction was determined to be the result of the restorative metals. Additionally, it was found during the investigation that the implants were placed 3 months after grafting with dynablast. Per the dfu, implant placement should begin approximately 6 months after grafting with dynablast. Review of labeling notes: warnings and precautions: sites grafted with dynablast should be allowed to heal approximately 6 months prior to implant placement.
Patient Sequence No: 1, Text Type: N, H10


[142613420] In (b)(6) 2011, the patient received dynablast paste in location #30. In (b)(6) 2011 she received an implant at the site and restoration was completed in (b)(6) 2011. In 2014, the patient began pulling fibrous strands out of the site. A pathology report was performed on (b)(6) 2014, and the results were inconclusive. In 2015, the patient began to experience inflammation and itching around the site and she continued to pull out fibrous strands. An additional pathology report was performed on (b)(6) 2015 which concluded that she had type iv hypersensitivity to the metals used in the restoration and all restorative components were removed. However, the patient continued to express signs of allergic reaction and fibrous strands. Patient was concerned that the issue may have been with the bone graft material. At the time of contact, no additional event information was available.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2090010-2019-00002
MDR Report Key8534704
Report SourceCOMPANY REPRESENTATIVE,DISTRI
Date Received2019-04-22
Date of Report2019-04-21
Date of Event2016-01-01
Date Mfgr Received2019-03-22
Date Added to Maude2019-04-22
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactSTEPHANIE CHAVEZ
Manufacturer Street5770 ARMADA DRIVE
Manufacturer CityCARLSBAD CA 92008
Manufacturer CountryUS
Manufacturer Postal92008
Manufacturer Phone7602165109
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameDYNABLAST PASTE 1CC
Generic NameBONE GRAFTING MATERIAL
Product CodeNUN
Date Received2019-04-22
Model Number10-210-1060
Lot Number102268
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerSEASPINE INC.
Manufacturer Address2 GOODYEAR IRVINE CA 92618 US 92618


Patients

Patient NumberTreatmentOutcomeDate
101. Other 2019-04-22

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.